GenFleet Therapeutics (Shanghai) Inc. Stock
Stocks
2595
CNE1000074L2
Biotechnology & Medical Research
|
Market Closed -
Hong Kong S.E.
12:08:25 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 26.86 HKD | -1.25% |
|
-9.56% | +12.95% |
| 10-27 | GenFleet Therapeutics Inc. Presents Initial Clinical Readout Of GFH276 At 2026 ESMO Annual Meeting | CI |
| 10-15 | GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3% | MT |
| Market Cap | 8.45B 9.95B 1.27B 1.14B 1.05B 953M 1.78B 121B 1.8B 12.58B 5.01B 63.19B 4.76B 4.66B 201B | P/E 2026 * |
-11.7x | P/E 2027 * | -42.9x |
|---|---|---|---|---|---|
| Enterprise Value | 6.49B 7.64B 974M 874M 808M 732M 1.37B 92.76B 1.38B 9.66B 3.85B 48.54B 3.65B 3.58B 154B | EV / Sales 2026 * |
73.5x | EV / Sales 2027 * | 24.6x |
| Free-Float |
73.9% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2595 | Delayed | |
Tradegate
| Y3L | Real-time | |
|
Boerse Muenchen
| Y3L | Real-time |
| 1 day | -1.25% | ||
| 1 week | -9.56% | ||
| Current month | -18.61% | ||
| 1 month | -10.17% | ||
| 3 months | -19.05% | ||
| 6 months | -44.16% | ||
| Current year | +12.95% |
| 1 week | 26.42 |  | 31.1 |
| 1 month | 25.22 | | 33.42 |
| Current year | 19.6 | | 52.9 |
| 1 year | 19.6 | | 52.9 |
| 3 years | 19.6 | | 52.9 |
| 5 years | 19.6 | | 52.9 |
| 10 years | 19.6 | | 52.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jiong Lan
CEO | Chief Executive Officer | 53 | 22/08/2017 |
Yu Wang
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2020 |
Wei Zhang
SEC | Corporate Secretary | 47 | 24/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jiong Lan
BRD | Director/Board Member | 53 | 22/08/2017 |
Qiang Lü
CHM | Chairman | 41 | 22/08/2017 |
Wei Zhang
BRD | Director/Board Member | 47 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.25% | -9.56% | -6.48% | - | 1.28B | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +1.76% | +2.10% | +12.10% | +81.21% | 54.55B | |
| -0.94% | +0.77% | +8.85% | +100.19% | 53.59B | |
| +2.76% | +4.18% | +28.34% | +55.07% | 44.75B | |
| +2.00% | -2.90% | +18.37% | +119.04% | 41.62B | |
| +1.34% | -3.98% | +225.44% | +914.08% | 39.91B | |
| +0.64% | -3.85% | +11.71% | +45.57% | 32.47B | |
| +29.06% | +48.65% | +106.84% | +92.73% | 26.7B | |
| +3.72% | -7.45% | +24.25% | -2.99% | 23.36B | |
| Average | +3.96% | -1.22% | +46.29% | +162.82% | 38.17B | |
| Weighted average by Cap. | +3.20% | -0.32% | +47.38% | +161.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 88.32M 104M 13.25M 11.89M 10.99M 9.95M 18.59M 1.26B 18.82M 131M 52.33M 660M 49.71M 48.66M 2.1B | 284M 334M 42.57M 38.19M 35.31M 31.98M 59.74M 4.05B 60.46M 422M 168M 2.12B 160M 156M 6.73B |
| Net income | -725M -853M -109M -97.52M -90.16M -81.65M -153M -10.35B -154M -1.08B -429M -5.42B -408M -399M -17.2B | -198M -234M -29.77M -26.71M -24.69M -22.36M -41.78M -2.84B -42.29M -295M -118M -1.48B -112M -109M -4.71B |
| Net Debt | -1.96B -2.31B -294M -264M -244M -221M -413M -28.01B -418M -2.92B -1.16B -14.66B -1.1B -1.08B -46.52B | -1.47B -1.72B -220M -197M -182M -165M -309M -20.94B -312M -2.18B -868M -10.96B -825M -807M -34.78B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | HK$26.86 | -1.25% | 2,506,200 |
| 27/10/26 | HK$27.20 | -3.13% | 1,423,764 |
| 26/10/26 | HK$28.08 | -6.34% | 3,952,800 |
| 23/10/26 | HK$29.98 | +1.63% | 2,807,369 |
| 22/10/26 | HK$29.50 | -4.22% | 5,560,700 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2595 Stock
Select your edition
All financial news and data tailored to specific country editions
